InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Secures U.S. Patent for Abuse-Deterrent Transdermal Technology
June 9, 2025
Nutriband (NASDAQ: NTRB) has been granted U.S. patent No. 12,318,492 for its “Abuse and Misuse Deterrent Transdermal Systems,” further strengthening domestic protection for its Aversa(TM) technology. The patent, issued June 3, 2025, enhances the company’s intellectual property portfolio for abuse-deterrent transdermal products designed to curb misuse, diversion, and accidental exposure. Aversa(TM) is currently in development […]
Nutriband Inc. (NASDAQ: NTRB) Advances Abuse-Deterrent Buprenorphine Therapy with AVERSA Technology
June 5, 2025
As the opioid epidemic continues to pose one of the most critical public health crises in the United States and around the world, the need for innovative, safer treatments has never been more urgent. One company, Nutriband (NASDAQ: NTRB), is aiming to transform how opioid-based therapies are administered and protected against misuse, using its proprietary […]
Nutriband Inc. (NASDAQ: NTRB): A Relentless Mission Rooted in Purpose, Innovation, and Shareholder Value
June 4, 2025
Serguei Melnik, Founder and President of Nutriband (NASDAQ: NTRB), recently joined The Smart Money Circle Show, where he pulled back the curtain on his no-nonsense approach to biotech entrepreneurship. His grounded tone and unwavering focus on long-term value stand in stark contrast to the conventional biotech playbook. As is typical, the topic of the article […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) to Present at Noble Capital Markets Emerging Growth Virtual Conference
June 3, 2025
Nutriband (NASDAQ: NTRB) announced that CEO Gareth Sheridan will present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on Thursday, June 5 at 4 p.m. ET. The session will feature a fireside-style Q&A open to live audience questions, with 1×1 meetings available for qualified investors. A webcast of the presentation will be accessible post-event […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Posts Record Q1 Revenue, Advances AVERSA Fentanyl Development
June 2, 2025
Nutriband (NASDAQ: NTRB) reported first-quarter revenue of $667,000, a 63% year-over-year increase driven by expanded kinesiology tape production through its Pocono Pharma subsidiary and growing retail presence at Target, Walmart, Walgreens, and CVS. The company continues to prioritize shareholder value by scaling Pocono’s output through penetration pricing strategies while advancing development of AVERSA Fentanyl, an […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) CEO Highlights Transdermal Pain Solution on BioMedWire Podcast
May 27, 2025
Nutriband (NASDAQ: NTRB) is featured in the latest episode of The BioMedWire Podcast, part of IBN’s expanding podcast network focused on biotech and pharmaceutical innovation. In a conversation with host Carmel Fisher, Nutriband Co-Founder and CEO Gareth Sheridan outlined the company’s focus on transdermal drug delivery systems, particularly in the underserved area of pain management. […]
Nutriband Inc. (NASDAQ: NTRB) Charts Path to Commercialization
May 22, 2025
In a recent report to shareholders, Nutriband (NASDAQ: NTRB) CEO Gareth Sheridan shared significant company achievements and milestones as well as his expectations for 2025 (https://ibn.fm/9K5zT). At the center of the company’s positive outlook for future is noteworthy progress made toward the commercialization of its proprietary Aversa technology, including a strong partnership with Kindeva Drug […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Strengthens Pharma Footprint Through Key Alliances
May 15, 2025
Nutriband (NASDAQ: NTRB), a company focused on the development of a portfolio of transdermal pharmaceutical products, is expanding its market presence and manufacturing capabilities through two new strategic partnerships. The company is collaborating with Charlotte FC to build brand visibility, particularly for its AI Tape and AVERSA(TM)—Nutriband’s proprietary technology that it believes has the potential […]
Nutriband Inc. (NASDAQ: NTRB) Pioneers Innovative Approach to Opioid Crisis with Game-Changing Transdermal Patch
May 13, 2025
As the opioid crisis continues to challenge public health systems, the need for innovative solutions has become increasingly apparent. Rather than relying solely on restrictive measures, companies such as Nutriband (NASDAQ: NTRB) are exploring technological advancements to mitigate abuse while ensuring patient access to necessary medications. Nutriband’s development of AVERSA(TM) Fentanyl, an abuse-deterrent transdermal patch, exemplifies […]
Nutriband Inc. (NASDAQ: NTRB) Innovating Abuse-Deterrent Drug Delivery in a Shifting Opioid Landscape
May 9, 2025
A Market Demanding Safer Opioid Solutions The opioid crisis remains a critical public health challenge in the U.S. and globally, prompting a series of new regulatory measures designed to improve safety and reduce misuse. In early 2025, the FDA approved Journavx (suzetrigine), a first-in-class non-opioid painkiller offering patients safer alternatives to opioids. Additionally, opioid manufacturers […]
Nutriband Inc. (NASDAQ: NTRB) Leadership Team: Driving Innovation and Shaping the Future of Global Healthcare
April 30, 2025
Nutriband (NASDAQ: NTRB) is earning widespread recognition for the board’s leadership, expertise and innovation across a variety of platforms. Sheridan has recently been acknowledged in several high-profile ways that affirm his growing influence as a respected professional in the healthcare and business sectors. From being named a finalist for the prestigious EY Entrepreneur of the […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) CEO Issues Shareholder Letter Highlighting 2024 Milestones and 2025 Commercialization Goals
April 30, 2025
Nutriband (NASDAQ: NTRB) has released a shareholder letter from CEO Gareth Sheridan outlining key achievements in 2024 and plans for 2025, centered on advancing its AVERSA™ abuse-deterrent transdermal technology. The company is transitioning from feasibility to commercial development of AVERSA Fentanyl in partnership with Kindeva Drug Delivery, targeting a pivotal Human Abuse Liability clinical trial […]
InvestorNewsBreaks – Why Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’
April 25, 2025
Nutriband (NASDAQ: NTRB), a company focused on the development of a portfolio of transdermal pharmaceutical products, was featured in a recent article that discussed its innovative AVERSA(TM) abuse-deterrent technology and business model. “AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that […]
Nutriband Inc. (NASDAQ: NTRB): Building a Moat Around Abuse-Deterrent Drug Delivery
April 22, 2025
Strengthening IP for Long-Term Market Protection Nutriband (NASDAQ: NTRB) continues to solidify its leadership in the development of abuse-deterrent transdermal pharmaceuticals. In February, the company received a trademark registration from the U.S. Patent and Trademark Office (“USPTO”) for “Nutriband(TM),” covering pharmaceutical and product R&D. This comes in addition to a newly granted patent in Macao […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) CEO Named EY Entrepreneur of the Year 2025 Finalist in Established Category
April 17, 2025
Nutriband (NASDAQ: NTRB) CEO Gareth Sheridan has been named a finalist in the Established category of the 2025 EY Entrepreneur of the Year Awards. Sheridan is one of 27 Irish entrepreneurs recognized for their leadership and impact, with finalists selected from across 24 companies generating more than €1 billion in annual revenue. Sheridan is being […]
Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’
April 15, 2025
Nutriband (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s AVERSA(TM) technology can be incorporated into any transdermal patch and includes aversive agents to prevent abuse, diversion, misuse and accidental exposure to drugs with abuse potential, specifically opioids. AVERSA technology has the potential to improve the safety profile of […]
Nutriband Inc. (NASDAQ: NTRB) Leading the Way in Transformative Partnerships Formed in Growing Pharma Sector
April 14, 2025
Strategic alliances are vital to success in the pharmaceutical sector, where innovation, regulatory navigation and market access are complex and resource-intensive. Collaborations between biotech firms, research institutions and major pharmaceutical companies accelerate drug development, reduce costs and enhance the likelihood of regulatory approval. Nutriband (NASDAQ: NTRB), a company focused on the development of a portfolio […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Secures Patent in Macao for AVERSA Abuse-Deterrent Technology
April 11, 2025
Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, has been granted a patent in Macao for its AVERSA™ abuse-deterrent transdermal technology. The patent, titled “Abuse and Misuse Deterrent Transdermal Systems,” was granted on Feb. 11 and recorded in Macao’s Official Bulletin on Mar. 5. This adds to Nutriband’s global IP portfolio, with coverage […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Signs Partnership Deal With Charlotte FC to Boost Brand Visibility
April 4, 2025
Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, has entered into an Associate Partnership agreement with Charlotte FC to raise awareness of its flagship brands, including AI Tape and AVERSA. The company plans to leverage the partnership to enhance exposure for AI Tape, which is manufactured in the Charlotte region through its Pocono Pharmaceutical […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Schedules Live Investor Webinar, Q&A Session
October 2, 2024
Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, will be part of an upcoming live webinar hosted by RedChip Companies. Scheduled for October 17, 2024, at 4:15 p.m. ET, the exclusive event will feature Gareth Sheridan, Founder and CEO, and Serguei Melnik, Founder and President. Sheridan and Melnik will share […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Announces Receipt of Notice of Allowance for China Patent Application Covering AVERSA(TM) Technology
September 24, 2024
Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, is announcing that its patent application, which protects its AVERSA(TM) abuse deterrent transdermal technology, has been allowed in China. This follows the receipt of a Notice of Allowance from the Chinese National Intellectual Property Administration (“CNIPA”) for the application entitled “Abuse and […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Inks Licensing Agreement to Use Bitrex(R) Aversive Agent for Flagship Product
September 20, 2024
Nutriband (NASDAQ: NTRB), a company engaged in the development of prescription transdermal pharmaceutical products, has signed a trademark licensing agreement for the use of Bitrex(R) brand denatonium benzoate. According to the announcement, Bitrex is the most bitter substance in the world, and Nutriband will be using it as an aversive agent in its lead product, […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Reports on Share Repurchase Program
September 17, 2024
Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, has authorized a share repurchase program to buy back up to $1 million of its common stock. According to the announcement, as of Sept. 16, 2024, the company had 11,106,185 shares of common stock outstanding. The company also reported that it is continuing to make progress […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Releases Q2 Report, AVERSA Fentanyl Update
September 4, 2024
Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, is reporting its Q2 2024 financial results for the period ending July 31, 2024. According to the report, the company ended the quarter in a strong cash position, reinforcing its ability to advance the development of its lead product, AVERSA(TM) Fentanyl, with a New Drug Application […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Execs to Participate in July 25 Investor Webinar
July 19, 2024
Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, is inviting investors to a live webinar. Scheduled for July 25, 2024, at 4:15 p.m. ET, this exclusive event will be hosted by RedChip Companies. During the webinar, Nutriband Chairman and President Serguei Melnik and CEO Gareth Sheridan will share insights into […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Obtains Notice of Allowance for Key Trademark Identified as ‘Integral’ to Platform Technology
July 15, 2024
Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”). According to the announcement, the notice means that the USPTO anticipates granting the trademark registration covering the mark “AVERSA” after completing administrative processes. Nutriband’s proprietary AVERSA(TM) abuse deterrent transdermal technology works […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Shares Update on Its AVERSA(TM) Fentanyl Product Development Program
June 20, 2024
Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, today provided an update on its AVERSA(TM) Fentanyl product development program. This comes as the company plans to complete scale-up of the commercial manufacturing process and move towards the single Phase 1 human abuse potential study prior to a New Drug Application […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Releases Q1 2024 Quarterly Report
June 3, 2024
Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceuticals and technology, is reporting its first-quarter 2024 revenues. According to the report, the company saw revenues of $408,532 while also strengthening its balance sheet with the completion of an $8.4 million private placement involving existing and new shareholders; shares for the placement were offered at $4 per […]
InvestorNewsBreaks – Why Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’
May 31, 2024
Nutriband (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. “The company’s AVERSA(TM) can be incorporated into any transdermal patch and includes aversive agents to prevent misuse and accidental exposure to drugs with abuse potential, specifically opioids. AVERSA technology has the potential to improve the safety profile of transdermal drugs […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Schedules Live Investor Webinar, Q&A Session
May 21, 2024
Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceuticals and technology, will be spotlighted in an upcoming webinar, hosted by RedChip Companies. The event is slated for May 30, 2024, and will begin at 4:15 p.m. ET. Nutriband chair Serguei Melnik and CEO Gareth Sheridan will present during the event, which will provide key information for […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Names Seasoned Business Leader to Board of Directors
May 16, 2024
Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical solutions, has announced a new member of its board of directors. According to the announcement, Sergei Glinka, a seasoned and highly respected business executive, will serve on the board. An Estonian citizen, Glinka has served in several executive and board roles positions in large European companies, including […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Featured in Upcoming RedChip Small, Big Money(TM) Show
May 10, 2024
Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, is featured in an upcoming interview on the RedChip Small Stocks, Big Money(TM) show. During the program, which is scheduled to air on Bloomberg TV this Saturday, May 11, at 7 p.m. ET, Gareth Sheridan, Founder and CEO of Nutriband, will provide […]
Fentanyl Scourge: Nutriband Inc.’s (NASDAQ: NTRB) New Transdermal Patch with Abuse-Deterrent Tech Funded to Seek FDA Approval
May 6, 2024
Fentanyl addiction continues to devastate communities, with current treatment options facing limitations. However, as often happens in healthcare, innovation breeds hope with a new option on the horizon planning to seek FDA marketing approval. The challenges related to the powerful painkiller (up to 50x stronger than heroin and 100x stronger than morphine) are well documented. […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Engages IBN for Corporate Communications Expertise
April 25, 2024
Nutriband (NASDAQ: NTRB, NTRBW), a pharmaceutical company with a special focus on transdermal technologies, today announced that it has selected IBN, a multifaceted financial news and publishing company for private and public entities, to assist with its corporate communications initiatives. According to the announcement, Nutriband’s AVERSA(TM) technology can be incorporated into any transdermal patch and […]
IBN Coverage Initiated for Nutriband Inc.
April 25, 2024
LOS ANGELES, April 25, 2024 (GLOBE NEWSWIRE) — via IBN – Nutriband Inc. (NASDAQ: NTRB), a pharmaceutical company with a specific focus on transdermal technologies, today announces it has selected IBN, a multifaceted financial news and publishing company for private and public entities, to assist with its corporate communications initiatives. Nutriband’s AVERSA™ technology can be incorporated into any transdermal […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Closes $8.4M Private Placement
April 24, 2024
Nutriband (NASDAQ: NTRB, NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has closed an $8.4 million private placement to fund the commercial development program for its lead product, AVERSA(TM) Fentanyl. AVERSA Fentanyl has the potential to be the world’s first abuse-deterrent opioid patch designed to deter the […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Enters Exclusive Supplier Agreement with Major Sports Brand Licensee
April 23, 2024
Nutriband (NASDAQ: NTRB, NTRBW) today announced that following its engagement by Fit For Life Group (“FFL”), a major brand license holder, on April 19, 2024, the companies fully executed an exclusive supplier agreement for FFL’s new product launch under one of its top brands. According to the announcement, Nutriband’s wholly owned contract manufacturing subsidiary, Active […]
Nutriband Inc. (NASDAQ: NTRB) Advances Abuse Deterrent Tech Addressing Fentanyl Epidemic
April 23, 2024
Fentanyl, a potent opioid, poses a significant problem due to its potential for abuse with a high risk of overdose – even in small quantities. Nutriband (NASDAQ: NTRB) is advancing its AVERSA(TM) technology that features aversive agents to prevent abuse, diversion, misuse, and accidental exposure to drugs with abuse potential, specifically opioids. “AVERSA is a […]
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Enters Into Private Placement Agreements to Raise Funds for Development of AVERSA Fentanyl
April 19, 2024
Nutriband (NASDAQ: NTRB), a company engaged in the development of abuse-deterrent pharmaceutical products, has entered into definitive securities purchase agreements. The agreements are for the purchase and sale of up to 2,100,000 shares of common stock, with each share offered at $4 per share. According to the announcement, for each share of common stock purchased […]
Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’
April 10, 2024
Nutriband (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s AVERSA(TM) technology can be incorporated into any transdermal patch and includes aversive agents to prevent abuse, diversion, misuse and accidental exposure to drugs with abuse potential, specifically opioids. AVERSA technology has the potential to improve the safety profile […]